SUPPRELIN by Takeda is continuously. Approved for children with central precocious puberty (cpp), children with central precocious puberty (cpp) (). First approved in 1991.
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
SUPPRELIN is a histrelin acetate subcutaneous implant delivering ~65 mcg daily that treats central precocious puberty (CPP) in children. It works via GnRH receptor agonism, causing initial gonadotropin stimulation followed by sustained down-regulation and desensitization, resulting in suppression of gonadal steroid production. The implant provides continuous long-acting hormone suppression to halt premature sexual development.
As LOE approaches, the brand team is likely optimizing lifecycle extension strategies while preparing for generic erosion; moderate-sized commercial organization focused on specialty pediatric endocrinology.
continuously. It delivers approximately 65 mcg histrelin acetate per day. Both animal and human studies indicate that following an initial stimulatory phase, chronic, subcutaneous administration of histrelin acetate desensitizes responsiveness of the pituitary gonadotropin which, in turn causes a…
Worked on SUPPRELIN at Takeda? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on SUPPRELIN offers stable specialty pharma experience in a rare pediatric indication but presents limited upside due to LOE approach and niche market size. Career growth likely dependent on defensive market strategies and cross-functional roles bridging commercial and medical functions.